日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Simultaneously complete but not partial taste and smell losses were associated with SARS-CoV-2 infection

同时出现完全性而非部分性味觉和嗅觉丧失与SARS-CoV-2感染相关。

Trachootham, Dunyaporn; Thongyen, Supeda; Lam-Ubol, Aroonwan; Chotechuang, Nattida; Pongpirul, Wannarat; Prasithsirikul, Wisit

CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1

CYP2B6 18492T->C 多态性会降低携带 CYP2B6 单倍型 *1/*1 的 HIV 合并结核病患者的依非韦伦浓度。

Manosuthi, Weerawat; Sukasem, Chonlaphat; Thongyen, Supeda; Nilkamhang, Samruay; Manosuthi, Sukanya; Sungkanuparph, Somnuek

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients

CYP2B6 药理遗传学标志物、临床因素和药物相互作用对 HIV/结核病合并感染患者依非韦伦浓度的影响

Manosuthi, Weerawat; Sukasem, Chonlaphat; Lueangniyomkul, Aroon; Mankatitham, Wiroj; Thongyen, Supeda; Nilkamhang, Samruay; Manosuthi, Sukanya; Sungkanuparph, Somnuek

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure

在经历核苷类逆转录酶抑制剂(NRTI)和非核苷类逆转录酶抑制剂(NNRTI)治疗失败的HIV感染者中,利托那韦增强的洛匹那韦单药治疗的长期疗效。

Manosuthi, Weerawat; Thongyen, Supeda; Nilkamhang, Samruay; Manosuthi, Sukanya; Sungkanuparph, Somnuek

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure

在对核苷类逆转录酶抑制剂(NRTI)和非核苷类逆转录酶抑制剂(NNRTI)治疗失败的HIV感染者中,利托那韦增强的洛匹那韦单药治疗的治疗结果和血浆浓度。

Manosuthi, Weerawat; Kiertiburanakul, Sasisopin; Amornnimit, Wannarat; Prasithsirikul, Wisit; Thongyen, Supeda; Nilkamhang, Samruay; Ruxrungtham, Kiat; Sungkanuparph, Somnuek